Personal

Ticket to Biotech

No refunds will be administered. Be sure that you're an accepted T2B member before paying for your ticket.

***If you're a T2B member and do not receive your confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the cal invite.***

If you're not part of Ticket to Biotech, 

, and join before registering for this event:

Hosted by Alkermes and in partnership with Biosector 2, this come-and-go networking event is open to all biopharma communicators in the T2B community. Come mix and mingle with fellow comms pros!

Complimentary snacks and drinks will be provided. ​See you there!

New at the Q3 T2Bmeet @ Boston: Coaches Corner 

Get focused support for a real workplace challenge in a 20-minute Power Coaching Session with leadership coaches 

. Both bring deep experience working with communications professionals and leaders in the biotech industry. Use your session to think through a decision, team dynamic, difficult conversation, or other pressing challenge and leave with greater clarity, confidence, and practical next steps. Sessions will be available during the event’s networking portions, with onsite sign-up when you arrive.

Panel Discussion: Staying Relevant Between Milestones

In biopharma, attention spikes around data readouts, regulatory decisions, financings, partnerships, and launches. We're the ones responsible for keeping a company's story alive in between, translating steady, unglamorous progress into something stakeholders can still follow. Yet staying visible between catalysts means walking a line: go too quiet and the narrative stalls, say too much and it starts to look manufactured. This panel opens a discussion on how communicators sustain narrative momentum between major catalysts, decide which interim stories are worth telling, and protect credibility for when it matters most.

Katie Joyce, Vice President of Corporate Affairs, Alkermes

 is the Vice President for Corporate Affairs for Alkermes, a biopharma company focused on developing medicines for people living with psychiatric and neurological disorders. Her team is responsible for all external, internal and product communications, as well as patient advocacy. Prior to this role, Katie had roles of increasing responsibility at Takeda and Shire. Katie made the switch to industry after almost fifteen years working government, most recently for Deval Patrick, former Governor of Massachusetts. She is a Board member at the Massachusetts Business Roundtable and previously served on the Massachusetts Board of Early Education and Care and the Governor’s Task Force on Women in Work. Katie holds a BA from Boston College and a MPA from The George Washington University.

Carlo Tanzi, Ph.D., Founder and Principal, Kendall Investor Relations

, is Founder and Principal of Kendall Investor Relations, a biotech-focused firm advising private and public companies on investor strategy, positioning, and execution across financings. He founded the firm in 2018.

Before founding Kendall IR, Carlo was Vice President of Investor Relations and Corporate Communications at Seres Therapeutics, where he served on the leadership team. Earlier, he spent nine years at Biogen in investor relations and program management roles, including Director of Investor Relations and Program Management Lead for Tecfidera and Tysabri. He began his career as a healthcare management consultant at Health Advances.

His IR experience spans multiple product launches, IPO and follow-on financings, clinical data readouts, R&D investor days, sell-side engagement, and investor targeting. He holds a Ph.D. in molecular biology from the University of Pennsylvania.

Alina Worth, Managing Director, Biosector 2

Alkermes applies its decades of deep neuroscience expertise to develop medicines designed to help people living with complex, chronic psychiatric and neurological disorders. A global biopharmaceutical company headquartered in Dublin, Ireland, with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of important new medicines in areas which are often overlooked, including addiction, serious mental illness and sleep disorders. Visit 

Biosector 2 is built around a model that prioritizes senior expertise and long-term relationships in healthcare communications. Part of Syneos Health, the agency operates exclusively in healthcare and life sciences, working with companies navigating high-stakes moments where scientific, regulatory and reputational pressures intersect. Rather than scaling through volume, it has leaned into depth — embedding senior advisors directly into client work.

That approach is reflected in its structure. The agency’s “Brain Bank” model gives teams rapid access to specialized expertise across the firm, often delivering coordinated guidance within hours on complex issues.

Growth has followed from those relationships. More than two-thirds of 2025 growth came from existing clients through expanded scopes and new assignments, with more than half of clients remaining on the roster for three years or longer.

The work focuses on translating complex science into communications that resonate across audiences. Recent programs include campaigns raising awareness of RSV protection among parents through trusted voices and community engagement, as well as storytelling initiatives centered on lived experiences within rare disease communities.

That emphasis on connection extends internally. The agency’s culture is built around mentorship and knowledge-sharing, with long-tenured leadership and structured programs linking senior advisors with emerging talent. Leadership tenure averages more than 15 years.  The result is a firm that has chosen to deepen expertise and relationships in a sector where both are critical to navigating uncertainty.

Q3 T2Bmeet @ Boston 2026